Answers are grounded in this paper and cite their sources.
To explore the clinical data and review the literature on successful robotic-assisted hepatectomy after yttrium-90 microsphere radioembolization (Y 90 -RE) combined with targeted therapy and immunotherapy for advanced unresectable hepatocellular carcinoma (HCC). We retrospectively analyzed a case of with advanced HCC patient in our center who successfully underwent robotic-assisted hepatectomy after Y 90 -RE combined with targeted therapy and immunotherapy. Additionally, we reviewed the related treatments and summarized the latest advances in domestic and international literature. The patient was a 65-year-old man, who underwent successful robotic-assisted hepatectomy after Y 90 -RE combined with targeted immunotherapy and was confirmed to achieve pathologically complete remission (pCR). Postoperative pathology showed that the tumor was necrotic, and no tumor residue was observed. The patient was followed up for more than six months, and no tumor recurrence was observed. In this case, Y 90 -RE combined with targeted immunotherapy as a preoperative conversion therapy option for advanced unresectable HCC was proven to be safe and feasible in this case.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: